JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Inclusion Criteria:

1. Signed the informed consent form (ICF);

2. Recurrent or advanced stage Ⅲ B or IV non-small cell lung cancer tested for EGFRmutation and ALK, ROS1 fusion gene, and all the driving gene was negative.

3. At least one measurable lesion (according to RECIST 1.1);

4. Failure of previous first-line standard chemotherapy:

5. Patients who agreed to provide previously stored tumor tissue specimens or freshbiopsies of tumor lesions

6. Age 18-75 years old, regardless of gender;

7. ECOG score 0-1;

8. Expected survival time ≥ 3 months;

9. Laboratory test value must show enough organ function

Exclusion Criteria:

1. Tumor histology or cytological pathology confirmed the presence of small cell lungcancer components, or sarcomatoid lesions;

2. Those who did not have a driving gene test;

3. Investigator believed that there was a clear bleeding tendency

4. Subjects who are currently participating in and receiving treatment in other studies,less than 4 weeks

5. Patients who had previously received second-line or more systemic chemotherapy foradvanced NSCLC;

6. Patients who had received hematopoietic stimulating factors, within one week beforethe start of the study.

7. Uncontrollable or symptomatic hypercalcemia

8. Within 6 months before receiving the study treatment, they received chest (lung)radiotherapy > 30Gy, or received radiotherapy within 4 weeks or radiopharmaceuticalswithin 8 weeks, except for local palliative radiotherapy for bone metastases.

9. The adverse reactions of previous antineoplastic therapy have not yet recovered toCTCAE 5.0 grade ≤ 1 (except alopecia);

10. Major surgery or radiotherapy has been performed within 4 weeks before joining thegroup or has not yet fully recovered from the previous operation

11. Known active central nervous system (CNS) metastasis and / or cancerous meningitis;

12. Spinal cord compression without radical treatment of surgery and / or radiotherapy;

13. Uncontrolled tumor-related pain;

14. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeateddrainage ;

15. Evidence of active pneumonia was found;

16. Clinically uncontrolled active infections;

17. Uncontrollable major seizures or superior vena cava syndrome;

18. Past or present co-existence of other malignant tumors;

19. Liver diseases known to be of clinical significance;

20. Those who have previously used any anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2antibody or anti-CTLA-4 antibody and Axitinib;

21. Patients with active tuberculosis (TB);

22. Patients with any active autoimmune disease or history of autoimmune disease;

23. Any anti-infective vaccine;

24. Known (HIV) infection of human immunodeficiency virus;

25. The researchers believe that it can affect study compliance;

26. Patients who received systemic immunosuppressive drugs within the first 4 weeks of thefirst day of the first cycle;

27. History of severe allergy, anaphylaxis or other hypersensitivity to chimeric orhumanized antibodies or fusion proteins;

28. Those who are known to be allergic to biological drugs;

29. Those who are known to be allergic to acitinib;

30. Patients with a history of arterial or venous thromboembolism;

31. Known hereditary or acquired bleeding and thrombotic tendencies;

32. Patients who have previously received allogeneic stem cell or parenchyma organtransplantation;

33. Pregnant or lactating women or women of childbearing age who were positive for serumpregnancy test before taking the drug for the first time